US Pharma MarketingThe post Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex appeared first on Clinical Trials Arena.
Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex
Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex as a monotherapy for people with advanced solid tumours carrying BRCA1/2 or partner and localiser of PALB2. The study’s next steps are data review, database lock, statistical analysis, and a clinical study report in 2027. Senhwa develops cancer therapies and advances a pipeline with CX-5461, CX-4945 for solid tumours and haematological malignancies. Credit: Sai Thaw Kyar / Shutterstock.com. Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex (CX-5461) as a monotherapy for people with advanced solid tumours carrying breast cancer gene 1/2 (BRCA1/2)…
Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex as a monotherapy for people with advanced solid tumours carrying BRCA1/2 or partner and localiser of PALB2.
Source: Clinical Trials Arena